MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 208498 | Name: Pitavastatin lactone
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pitavastatin lactone is a statin that targets aggressive low-density lipoprotein cholesterol (LDL-C)-lowering therapy in clinical practice

Chemical Structure

Pitavastatin lactone
Pitavastatin lactone
CAS#141750-63-2 (lactone)

Theoretical Analysis

MedKoo Cat#: 208498

Name: Pitavastatin lactone

CAS#: 141750-63-2 (lactone)

Chemical Formula: C25H22FNO3

Exact Mass: 403.1584

Molecular Weight: 403.45

Elemental Analysis: C, 74.43; H, 5.50; F, 4.71; N, 3.47; O, 11.90

Price and Availability

Size Price Availability Quantity
10mg USD 350.00 2 Weeks
25mg USD 685.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
147526-32-7 (calcium) 147511-69-1 (free acid) 141750-63-2 (lactone) 849811-78-5 (methyl ester)
Synonym
IUPAC/Chemical Name
(4R,6S)-6-((E)-2-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)vinyl)-4-hydroxytetrahydro-2H-pyran-2-one
InChi Key
XJVKVAFYQRWVAJ-MCBHFWOFSA-N
InChi Code
InChI=1S/C25H22FNO3/c26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-19-13-18(28)14-23(29)30-19/h1-4,7-12,16,18-19,28H,5-6,13-14H2/b12-11+/t18-,19-/m1/s1
SMILES Code
O[C@@H]1C[C@H](OC(=O)C1)\C=C\c2c(nc3ccccc3c2c4ccc(F)cc4)C5CC5
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 403.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Chan P, Shao L, Tomlinson B, Zhang Y, Liu ZM. An evaluation of pitavastatin for the treatment of hypercholesterolemia. Expert Opin Pharmacother. 2019 Jan;20(1):103-113. doi: 10.1080/14656566.2018.1544243. Epub 2018 Nov 27. PMID: 30482061. 2: Saku K, Zhang B, Noda K; PATROL Trial Investigators. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ J. 2011;75(6):1493-505. doi: 10.1253/circj.cj-10-1281. Epub 2011 Apr 15. PMID: 21498906. 3: Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, Ogawa T, Ozaki Y, Sakuma I, Nakagawa Y, Hibi K, Hiro T, Fukumoto Y, Hokimoto S, Miyauchi K, Yamazaki T, Ito H, Otsuji Y, Kimura K, Takahashi J, Hirayama A, Yokoi H, Kitagawa K, Urabe T, Okada Y, Terayama Y, Toyoda K, Nagao T, Matsumoto M, Ohashi Y, Kaneko T, Fujita R, Ohtsu H, Ogawa H, Daida H, Shimokawa H, Saito Y, Kimura T, Inoue T, Matsuzaki M, Nagai R. High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial. Circulation. 2018 May 8;137(19):1997-2009. doi: 10.1161/CIRCULATIONAHA.117.032615. Erratum in: Circulation. 2019 Apr 2;139(14):e836. PMID: 29735587; PMCID: PMC5959207. 4: Adams SP, Alaeiilkhchi N, Wright JM. Pitavastatin for lowering lipids. Cochrane Database Syst Rev. 2020 Jun 19;6(6):CD012735. doi: 10.1002/14651858.CD012735.pub2. PMID: 32557581; PMCID: PMC7387421. 5: Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract. 2005 Feb;59(2):239-52. doi: 10.1111/j.1742-1241.2005.00461.x. PMID: 15854203. 6: Hoy SM. Pitavastatin: A Review in Hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168. doi: 10.1007/s40256-017-0213-8. PMID: 28130659. 7: Saito Y. Pitavastatin: an overview. Atheroscler Suppl. 2011 Nov;12(3):271-6. doi: 10.1016/S1567-5688(11)70886-8. PMID: 22152281. 8: Filippatos TD, Elisaf MS. Pitavastatin and carbohydrate metabolism: what is the evidence? Expert Rev Clin Pharmacol. 2016 Jul;9(7):955-60. doi: 10.1586/17512433.2016.1165607. Epub 2016 Mar 28. PMID: 26967972. 9: Cheon YH, Lee CH, Kim S, Park GD, Kwak SC, Cho HJ, Kim JY, Lee MS. Pitavastatin prevents ovariectomy-induced osteoporosis by regulating osteoclastic resorption and osteoblastic formation. Biomed Pharmacother. 2021 Jul;139:111697. doi: 10.1016/j.biopha.2021.111697. Epub 2021 May 13. PMID: 34243614. 10: Catapano AL. Pitavastatin - pharmacological profile from early phase studies. Atheroscler Suppl. 2010 Dec;11(3):3-7. doi: 10.1016/S1567-5688(10)71063-1. PMID: 21193152.